Nanoparticles as a Delivery System for Conventional drugs and Herb-Derived Compounds for Cancer Therapy| Chapter 8 | Challenges and Advances in Pharmaceutical Research Vol.3

The purpose of this paper is to look at how pharmacokinetic studies of nanoparticles loaded in conventional pharmaceuticals and herb-derived chemicals can be used to treat cancer. The pharmacokinetic features of many herbal medicines and chemotherapeutic drugs integrated into nanoparticles were studied. The AUC of the plasma concentration-time profile, the maximum plasma concentration (Cmax), the time to maximum plasma concentration (Tmax), the volume of distribution (Vd or Vss), the elimination half-life (t 12), and clearance were all included (CL). Until February 2019, the systematic review was conducted utilising the PubMed and Science Direct databases. According to this systematic study, polymeric nanoparticles were the most extensively used nanocarrier to enhance pharmacokinetic properties. As a revolutionary drug delivery technique, nanoparticles have the potential to enhance the pharmacokinetics and cytotoxicity of loaded drugs/herb-derived substances for cancer treatment.

Author(s) Details:

Abdifetah Ibrahim Omar,
Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand and Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand.

Nadda Muhamad,
Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand and Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand.

Tullayakorn Plengsuriyakarn,
Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand and Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand.

Kesara Na-Bangchang,
Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand and Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand and Drug Discovery Center, Thammasat University, Pathumthani, Thailand.

Please see the link here: https://stm.bookpi.org/CAPRV-3/article/view/6948